Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce
Abstract Background Although it has been shown that allergen immunotherapy (AIT) is well‐tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed. Methods The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to addre...
| 发表在: | Clinical and Translational Allergy |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| 格式: | 文件 |
| 语言: | 英语 |
| 出版: |
Wiley
2023-06-01
|
| 主题: | |
| 在线阅读: | https://doi.org/10.1002/clt2.12250 |
| _version_ | 1851919241037479936 |
|---|---|
| author | Julijana Asllani Dimitrios Mitsias George Konstantinou Eris Mesonjesi Fatmira Xhixha Esmeralda Shehu George Christoff Katia Noleva Michael Makris Xenofon Aggelidis Mirjana Turkalj Erceg Damir Ioana Agache Vesna Tomic‐Spiric Rajica Stosovic Zeynep Misirligil Mitja Kosnik Todor A. Popov Moises Calderon Nikolaos G. Papadopoulos ADER study group |
| author_facet | Julijana Asllani Dimitrios Mitsias George Konstantinou Eris Mesonjesi Fatmira Xhixha Esmeralda Shehu George Christoff Katia Noleva Michael Makris Xenofon Aggelidis Mirjana Turkalj Erceg Damir Ioana Agache Vesna Tomic‐Spiric Rajica Stosovic Zeynep Misirligil Mitja Kosnik Todor A. Popov Moises Calderon Nikolaos G. Papadopoulos ADER study group |
| author_sort | Julijana Asllani |
| collection | DOAJ |
| container_title | Clinical and Translational Allergy |
| description | Abstract Background Although it has been shown that allergen immunotherapy (AIT) is well‐tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed. Methods The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved. Patient‐ and AIT‐related features were collected and analyzed. The characteristics of adverse events (AE) and risk factors were evaluated. Results A total of 851 patients, 11.3 ± 3.4 years old, with rhinitis only (47.6%); asthma and rhinitis (44.5%); asthma (7.9%), receiving 998 AIT courses were analyzed. Sublingual immunotherapy (SLIT) accounted for 51% of the courses. In 84.5% of patients only one AIT treatment was prescribed. Pollen was the most frequent sensitizer (57.1%), followed by mites (53.4%), molds (18.2%) and epithelia (16.7%). Local and systemic AEs were reported in 85 patients (9.9%). Most AEs (83.1%) were mild and occurred in <30 min (87%). Respiratory and cutaneous symptoms were more frequent. Only 4 patients (0.47%) had severe AE (none after 6 weeks of maintenance). The risk of AE was higher in patients undergoing SCIT. Conclusions AIT is safe and well tolerated in children and adolescents with respiratory allergies in real‐life clinical practice. Though SCIT is more prone to AE compared to SLIT, overall severe reactions are rare and occur during build‐up and early maintenance. |
| format | Article |
| id | doaj-art-77464b7b4e1c4d2fb2aa2bc8cfdbd1bd |
| institution | Directory of Open Access Journals |
| issn | 2045-7022 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| spelling | doaj-art-77464b7b4e1c4d2fb2aa2bc8cfdbd1bd2025-08-19T21:58:57ZengWileyClinical and Translational Allergy2045-70222023-06-01136n/an/a10.1002/clt2.12250Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforceJulijana Asllani0Dimitrios Mitsias1George Konstantinou2Eris Mesonjesi3Fatmira Xhixha4Esmeralda Shehu5George Christoff6Katia Noleva7Michael Makris8Xenofon Aggelidis9Mirjana Turkalj10Erceg Damir11Ioana Agache12Vesna Tomic‐Spiric13Rajica Stosovic14Zeynep Misirligil15Mitja Kosnik16Todor A. Popov17Moises Calderon18Nikolaos G. Papadopoulos19ADER study groupUniversity of Medicine Tirana AlbaniaAllergy Department 2nd Pediatric Clinic University of Athens Athens GreeceDepartment of Allergy and Clinical Immunology 424 General Military Training Hospital Thessaloniki GreeceUniversity Hospital Center “Mother Teresa” Tirana AlbaniaAmbulatory Polyclinic of Specialties, Nr. 3 Tirana AlbaniaInternal Medicine Department Durres Regional Hospital Durres AlbaniaMedical University‐Sofia Faculty of Public Health Sofia BulgariaET Dr. K. Noleva IPSMP Sofia BulgariaImmunotherapy Outpatient Clinic Allergy Unit 2nd Department Dermatology and Venereology National and Kapodistrian University of Athens University General Hospital ‘Attikon’ Athens GreeceImmunotherapy Outpatient Clinic Allergy Unit 2nd Department Dermatology and Venereology National and Kapodistrian University of Athens University General Hospital ‘Attikon’ Athens GreeceSrebrnjak Children's Hospital Zagreb CroatiaSrebrnjak Children's Hospital Zagreb CroatiaFaculty of Medicine Transylvania University Brasov RomaniaClinic of Allergology and Immunology University Clinical Center of Serbia Belgrade SerbiaClinic of Allergology and Immunology University Clinical Center of Serbia Belgrade Serbiaİstinye University Faculty of Medicine Ankara Liv Hospital Ankara TurkeyUniversity Clinic of Respiratory and Allergic Diseases Golnik SloveniaUniversity Hospital "Sv Ivan Rilski" Sofia BulgariaSection of Allergy and Clinical Immunology Imperial College London‐NHLI London UKAllergy Department 2nd Pediatric Clinic University of Athens Athens GreeceAbstract Background Although it has been shown that allergen immunotherapy (AIT) is well‐tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed. Methods The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved. Patient‐ and AIT‐related features were collected and analyzed. The characteristics of adverse events (AE) and risk factors were evaluated. Results A total of 851 patients, 11.3 ± 3.4 years old, with rhinitis only (47.6%); asthma and rhinitis (44.5%); asthma (7.9%), receiving 998 AIT courses were analyzed. Sublingual immunotherapy (SLIT) accounted for 51% of the courses. In 84.5% of patients only one AIT treatment was prescribed. Pollen was the most frequent sensitizer (57.1%), followed by mites (53.4%), molds (18.2%) and epithelia (16.7%). Local and systemic AEs were reported in 85 patients (9.9%). Most AEs (83.1%) were mild and occurred in <30 min (87%). Respiratory and cutaneous symptoms were more frequent. Only 4 patients (0.47%) had severe AE (none after 6 weeks of maintenance). The risk of AE was higher in patients undergoing SCIT. Conclusions AIT is safe and well tolerated in children and adolescents with respiratory allergies in real‐life clinical practice. Though SCIT is more prone to AE compared to SLIT, overall severe reactions are rare and occur during build‐up and early maintenance.https://doi.org/10.1002/clt2.12250adverse eventsallergen immunotherapyreal‐life settingsrisk factors |
| spellingShingle | Julijana Asllani Dimitrios Mitsias George Konstantinou Eris Mesonjesi Fatmira Xhixha Esmeralda Shehu George Christoff Katia Noleva Michael Makris Xenofon Aggelidis Mirjana Turkalj Erceg Damir Ioana Agache Vesna Tomic‐Spiric Rajica Stosovic Zeynep Misirligil Mitja Kosnik Todor A. Popov Moises Calderon Nikolaos G. Papadopoulos ADER study group Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce adverse events allergen immunotherapy real‐life settings risk factors |
| title | Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce |
| title_full | Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce |
| title_fullStr | Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce |
| title_full_unstemmed | Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce |
| title_short | Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce |
| title_sort | adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies report from the allergen immunotherapy adverse events registry ader a european academy of allergy and clinical immunology taskforce |
| topic | adverse events allergen immunotherapy real‐life settings risk factors |
| url | https://doi.org/10.1002/clt2.12250 |
| work_keys_str_mv | AT julijanaasllani adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT dimitriosmitsias adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT georgekonstantinou adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT erismesonjesi adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT fatmiraxhixha adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT esmeraldashehu adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT georgechristoff adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT katianoleva adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT michaelmakris adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT xenofonaggelidis adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT mirjanaturkalj adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT ercegdamir adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT ioanaagache adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT vesnatomicspiric adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT rajicastosovic adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT zeynepmisirligil adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT mitjakosnik adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT todorapopov adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT moisescalderon adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT nikolaosgpapadopoulos adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce AT aderstudygroup adverseeventsinchildrenandadolescentsundergoingallergenimmunotherapyforrespiratoryallergiesreportfromtheallergenimmunotherapyadverseeventsregistryaderaeuropeanacademyofallergyandclinicalimmunologytaskforce |